---
title: "About Us"
excerpt: "SWS-Binformatics @ NSWHP, Newcastle NSW, Australia"
permalink: /about/
toc: true
---

## Who we are
State-wide service bioinformatics group (SWS-Binformatics) at NSWHP is a group of bioinformaticians and biologists working together to provide bioinformatics support to the NSW Health Pathology (NSWHP) and alliance health service providers across NSW, Australasia and beyond. We are based out of Newcastle NSW, Australia.          

## What we do
[NSWHP Genomics](https://www.pathology.health.nsw.gov.au/our-services/genomics) is a state-wide service that provides a wide range of genomic testing for patients from prenatal scanning to diagnostics of cancer and rare diseases.
### Past and Current Projects
#### 2021 
#### 2022 - 2023
Mackenzie's Mission is a national research project that aims to improve the detection and diagnosis of genetic conditions in babies and children.
#### 2023
NSWHP Genomics is a key partner in OMICO's flagship [PROSPECT](https://www.garvan.org.au/research/programs/precision-oncology/prospect) project, a national precision oncology program that aims to improve outcomes for patients with rare and difficult-to-treat cancers. [^1][^2]

## Contacting Us
In reqeusts of comments or collabrations, please in the first instance contact us via [Support Desk Email](mailto:nswpath-swsbioinformatics@health.nsw.gov.au). 

---
---
## __References__ <br>
[^1]: NSW Health Pathology. NSW Health Pathology staff are playing a key role in a new study aimed at opening up new, potentially life-saving treatment pathways for more than 23,000 Australians with rare, difficult-to-treat or incurable cancers, including ovarian, pancreatic and sarcomas. https://pathology.health.nsw.gov.au/articles/our-key-role-in-prospect, (2023). <br>

[^2]: Garvan Institute of Medical Research. $185 million investment to fast-track treatments for rare and ‘untreatable’ cancers. https://www.garvan.org.au/news-events/news/185-million-investment-to-fast-track-treatments-for-rare-and-2018untreatable2019-cancers, (2022).

